Recursion Pharmaceuticals Investor Day Presentation Deck | Slidebook.io

Recursion Pharmaceuticals Investor Day Presentation Deck

January 2023, 143 slides

| Recursion Pharmaceuticals

agenda | Recursion Pharmaceuticals

welcome remarks president and coo of recursion | Recursion Pharmaceuticals

welcome remarks martin of recursion | Recursion Pharmaceuticals

state of recursion founder | Recursion Pharmaceuticals

disclaimers | Recursion Pharmaceuticals

the industry faces pressure amidst declining efficiency in drug discovery | Recursion Pharmaceuticals

the industry faces pressure amidst declining efficiency in drug discovery | Recursion Pharmaceuticals

opportunity recursion was founded to conduct an experiment determine whether technology can create an inflection in the discovery efficiency curve | Recursion Pharmaceuticals

an experiment from the beginning | Recursion Pharmaceuticals

an experiment from the beginning | Recursion Pharmaceuticals

continuing to mature the value proposition multiple cycles of learning and iteration | Recursion Pharmaceuticals

continuing to mature the value proposition multiple cycles of learning and iteration | Recursion Pharmaceuticals

traditional discovery pipeline ideal discovery pipeline recursion is designed to impact drug productivity | Recursion Pharmaceuticals

failing faster and to spend less and go faster which recursion has demonstrated with leading indicators of efficiency | Recursion Pharmaceuticals

maturing the value proposition in | Recursion Pharmaceuticals

recursion leads the rise of enabled drug discovery | Recursion Pharmaceuticals

pipeline partnerships guidance on top line for program guidance on interim safety for program guidance on trial update on program guidance on trial start update on collaboration including state of partnered pipeline update on collaboration platform target disclosure for project gamma announcement of and releases strong in cash and cash equivalents at the end of with potential for increased revenue in the near term new today | Recursion Pharmaceuticals

our mission decode biology to radically improve lives | Recursion Pharmaceuticals

impact | Recursion Pharmaceuticals

lina vice president product vice president data science | Recursion Pharmaceuticals

literature drives discovery informs target based hypotheses data are an exhaust limited to testing hypotheses disparate data generation to individual programs and diseases linear process little cross program learning or iteration bespoke processes low dimensional assays platforms drive discovery unbiased target agnostic data are our fuel shape our hypotheses connected data across programs relatable high dimensional data virtuous cycles of atoms bits iterative feedback accelerates learning industrialized to scale standardization recursion map based approach is designed set the standard for drug in the century | Recursion Pharmaceuticals

industrializing drug discovery at recursion the big picture | Recursion Pharmaceuticals

biological tools tools computational tools recursion enables scale reliability and relatability of | Recursion Pharmaceuticals

biological tools model and manipulate disease biology billion | Recursion Pharmaceuticals

tools create scalable repeatable and reliable laboratory processes million | Recursion Pharmaceuticals

computational tools extract organize and analyze highly structured data | Recursion Pharmaceuticals

we build biological and chemical to map relationships across scales and understand the connectivity of the system wins | Recursion Pharmaceuticals

maps of biology chemistry eer rue | Recursion Pharmaceuticals

| Recursion Pharmaceuticals

| Recursion Pharmaceuticals

| Recursion Pharmaceuticals

| Recursion Pharmaceuticals

| Recursion Pharmaceuticals

traditional target based screens million compounds a single target | Recursion Pharmaceuticals

million compounds the entire genome recursion is generating exponentially more insights | Recursion Pharmaceuticals

industrializing drug discovery at recursion the big picture | Recursion Pharmaceuticals

hit with | Recursion Pharmaceuticals

multiple high dimensional validate and expand the total biological understanding of the disease model and hits industrialized program generation hit to lead | Recursion Pharmaceuticals

validates initial insights at scale a | Recursion Pharmaceuticals

digital animal studies build high dimensional signatures of animal behavior and health industrialized program progression | Recursion Pharmaceuticals

traditional animal studies recursion digital animal studies | Recursion Pharmaceuticals

traditional animal studies recursion digital animal studies | Recursion Pharmaceuticals

disease induction year digital tolerability week liability weeks recursion months real time week enables faster for critical animal studies | Recursion Pharmaceuticals

industrialized optimization | Recursion Pharmaceuticals

the impact reduce time to candidate selection from months to weeks make design analyze test sma our vision integrate digital and chemistry operations | Recursion Pharmaceuticals

design objective our vision to integrate digital and chemistry operations | Recursion Pharmaceuticals

mole a molecular foundation model for drug discovery analyze our vision to integrate digital and chemistry operations | Recursion Pharmaceuticals

test our vision to integrate digital and chemistry operations | Recursion Pharmaceuticals

make our vision to integrate digital and chemistry operations | Recursion Pharmaceuticals

scalable reliable relatable empowering scientists with modal maps | Recursion Pharmaceuticals

clinical opportunities laura senior vice president head of research | Recursion Pharmaceuticals

human genes the recursion enables a differentiated capacity to interrogate | Recursion Pharmaceuticals

challenging biology complex the recursion enables a differentiated capacity to interrogate | Recursion Pharmaceuticals

target alpha potential first in class with novel to enhance anti response | Recursion Pharmaceuticals

clinical target us patients diagnosed with cancer in recursion goal ideal combination improves patient response and minimizes immune related adverse events | Recursion Pharmaceuticals

clinical target evaluation of sensitization and resistance markers from public pooled screens in the recursion map identification of an unexpected gene similar to identification of novel dual targeting modifier monitor local immune engagement show immune based clearance and associated new target identified for annotated gene a inhibitor measure peripheral inflammation show reduced inflammatory risk potential first in class with enhance anti response | Recursion Pharmaceuticals

clinical target us patients diagnosed with cancer in in response tumor clearance alpha series achieves while minimizing peripheral inflammation | Recursion Pharmaceuticals

clinical target us patients diagnosed with cancer in in response tumor clearance alpha series achieves while minimizing peripheral inflammation | Recursion Pharmaceuticals

clinical target us patients diagnosed with cancer in in response alpha series achieves tumor while minimizing peripheral inflammation | Recursion Pharmaceuticals

clinical target us patients diagnosed with cancer in in response alpha series achieves tumor while minimizing peripheral inflammation cro | Recursion Pharmaceuticals

clinical target map guided compound optimization | Recursion Pharmaceuticals

clinical target dramatic improvement in cellular activity could easily redirect chemistry efforts captures total of compounds and uncovers changes missed by assays | Recursion Pharmaceuticals

clinical target map detected a divergent phenotype dramatic improvement in cellular activity could easily redirect chemistry efforts captures total of compounds and uncovers changes missed by assays | Recursion Pharmaceuticals

clinical target immediately series phenotype immediately redirects away from unwanted activity | Recursion Pharmaceuticals

clinical target recursion essential to discovering program insights and driving efficient compound optimization | Recursion Pharmaceuticals

target gamma novel adjacent target for potentially treating negative ovarian cancer | Recursion Pharmaceuticals

clinical target data from cohort analysis of phase prima trial for platinum sensitive ovarian cancer patients clinical benefit inhibitors is limited in negative proficient | Recursion Pharmaceuticals

clinical target has been advanced as a target to improve response in the proficient setting selective inhibition of over other especially is very challenging inhibition of target for example with may mimic inhibition of while mitigating toxicity due to inhibition novel adjacent potentially treating | Recursion Pharmaceuticals

clinical target proficient ovarian cancer tumor volume increase in rate to durability in combination novel adjacent induces regression alone or with | Recursion Pharmaceuticals

clinical target recursion guided digital tolerability with minimized unexpected safety risk of | Recursion Pharmaceuticals

clinical target alpha and gamma reaching enabling studies in continuing to augment our digital chemistry and predictive capabilities property assessment continuing to drive potential first in disease or first in class programs at greater and scale looking ahead beyond | Recursion Pharmaceuticals

application ben chief technology officer | Recursion Pharmaceuticals

map of biology spans knockouts of most of the human genome genes approved and commercially available compounds at concentrations and tens of thousands of control images million images and deep learning of cells over recursion major public release times than our previous combined leading field in open science | Recursion Pharmaceuticals

of recursion data | Recursion Pharmaceuticals

is a simplified version of one of recursion internal compound intelligence tools a to illustrate what can be done with this data this is not our flagship internal map we are providing this tool for basic exploration of compound compound and compound gene relationships across approved and commercially available compounds all plots and driven by this single highlighting the power and flexibility of our based platform leading field in open science using | Recursion Pharmaceuticals

the majority of the genes are blinded to facilitate a sneak peek offer glimpse pique interest with potential partners | Recursion Pharmaceuticals

for the field | Recursion Pharmaceuticals

offer a glimpse of the power of recursion internal data and tools to pique the interest of potential partners provide the of its kind to date to enrich the field and foster the next generation of computational biologists discover new methods and bright talent that we can bring in house goals releasing | Recursion Pharmaceuticals

clinical programs chief business officer interim chief medical officer | Recursion Pharmaceuticals

pipeline strategy internal pipeline discovery partnerships partnership strategy how we create value using our maps of biology and chemistry | Recursion Pharmaceuticals

our pipeline reflects the scale and breadth of our approach | Recursion Pharmaceuticals

for the treatment of symptomatic cerebral cavernous malformations | Recursion Pharmaceuticals

clinical description disease overview cerebral cavernous malformations | Recursion Pharmaceuticals

clinical non oncology orphan indication product prevalence is an under appreciated disease | Recursion Pharmaceuticals

clinical patient population large and diagnosable no approved medical therapy disease overview cerebral cavernous malformations | Recursion Pharmaceuticals

clinical novel therapeutic approach to cerebral cavernous malformations | Recursion Pharmaceuticals

clinical state of the field in | Recursion Pharmaceuticals

clinical a traditional approach fails | Recursion Pharmaceuticals

clinical an unbiased approach using on cellular images | Recursion Pharmaceuticals

clinical applied of the | Recursion Pharmaceuticals

clinical preclinical studies reduces lesion burden and ameliorates vascular defects in genetic mouse models of further confidence confirm insight | Recursion Pharmaceuticals

clinical mechanism of action | Recursion Pharmaceuticals

clinical phase studies well tolerated with no dose dependent adverse events in sad and mad mad study placebo further confidence confirming safety | Recursion Pharmaceuticals

clinical phase trial initiated in enrollment criteria outcome measures trial update sycamore underway | Recursion Pharmaceuticals

for the treatment of progressive neurofibromatosis type mutated | Recursion Pharmaceuticals

clinical patient population large and diagnosable rare autosomal dominant tumor syndrome resulting from inactivation of the gene which leads to deficiencies in the tumor suppressor protein merlin can be inherited or spontaneous of patients represent new mutations up to are mosaic manifestations and vestibular mean age at presentation years no approved medical therapy no approved drugs for surgery is standard of care when feasible location may make complete resection untenable leading to hearing loss facial paralysis poor balance and visual difficulty disease overview neurofibromatosis type | Recursion Pharmaceuticals

clinical intracranial threatens mortality if amenable surgical excision is primary intervention many patients have multiple that exhibit heterogenous behavior and asynchronous growth stasis or shrinkage of tumor could improve prognosis disease overview neurofibromatosis type | Recursion Pharmaceuticals

clinical identified as rescuing cells treated with insight from rescued loss of | Recursion Pharmaceuticals

clinical orally penetrating small molecule inhibitor mechanism of action | Recursion Pharmaceuticals

clinical preclinical studies demonstrated clear in efficacy in multiple tumor types shrinks vestibular in nude mice prevents growth regrowth of deficient model in mice further confidence confirming insight | Recursion Pharmaceuticals

clinical would be first in class inhibitor for treatment of appears well suited other inhibitors | Recursion Pharmaceuticals

clinical enrollment criteria outcome measures trial update poplar phase underway | Recursion Pharmaceuticals

for the treatment of familial adenomatous polyposis | Recursion Pharmaceuticals

clinical patient population easily identifiable autosomal dominant tumor predisposition syndrome caused by a mutation in the gene classic mutation hundreds to thousands of polyps in colon and upper tract manifestations desmoid tumors likelihood of developing cancer before age if untreated disease overview familial adenomatous polyposis | Recursion Pharmaceuticals

clinical no approved medical therapy standard of care colectomy during adolescence with or without removal of rectum post colectomy patients still at significant risk of polyps progressing to cancer significant decrease in quality of life post colectomy continued endoscopies and surgical intervention despite progress with surgical management the need for effective therapies for remains high due to continued risk of tumors post surgery disease overview familial adenomatous polyposis | Recursion Pharmaceuticals

clinical rescued phenotypic defects of cells with knockdown compared to thousands of other molecules tested rescued phenotypic defects substantially better including better rescue than other inhibitors for specific knockdown findings validated in tumor cell lines and grown from human epithelial tumor cells with mutation more selectivity in tumor cell lines with mutation inhibited growth and organization of insight loss | Recursion Pharmaceuticals

clinical orally small molecule inhibitor disease state impact blocks mutation induced signaling are | Recursion Pharmaceuticals

clinical further confidence preclinical studies confirming reduction in polyp count and high grade dysplasia | Recursion Pharmaceuticals

clinical single center double blind placebo controlled dose study in healthy volunteers accomplished further confidence data generated by recursion | Recursion Pharmaceuticals

clinical phase trial initiated in enrollment criteria outcome measures trial update tupelo for underway | Recursion Pharmaceuticals

for the treatment of solid tumors with mutant cancers | Recursion Pharmaceuticals

clinical sustained signaling is a frequent driver event found across a wide variety of solid tumors of destruction complex due to inactivating mutations in leads to sustained signaling promoting cancer progression and survival mutant solid tumors are considered clinically aggressive and resistant to standard treatments disease overview cancers | Recursion Pharmaceuticals

clinical flexible patient selection strategy and study design disease overview mutant cancers | Recursion Pharmaceuticals

clinical dosage hypothesis rescue of may impact tumor progression and or restore sensitivity in cancers driven by loss recursion differentiation rescues tumor suppressor genes and and are negative regulators of signaling both proteins form part of the destruction complex strong clustering suggests map recapitulation of this biology insight from novel insight around established | Recursion Pharmaceuticals

clinical efficacy found in in mice models led to significant progression free survival further confidence preclinical studies confirming insight | Recursion Pharmaceuticals

clinical finalize design of a phase enriched trial initiate phase trial in select tumor types in early identify suitable partners for genetic testing capabilities evaluate in combination with targeted and or immune modulating agents next steps | Recursion Pharmaceuticals

for the treatment of difficile infection | Recursion Pharmaceuticals

clinical disease overview difficile infection | Recursion Pharmaceuticals

See More

Recursion Pharmaceuticals

Investor Day Presentation Decks

Biotechnology Decks

Healthcare Decks

Explore Topics

Tumor

Cancer

Drug discovery

Solid tumor

Data science

Related decks

Nuvectis Pharma

Investor Presentation

July 2023

Immix Biopharma

Investor Presentation

August 2023

RenovoRx

IPO

August 2021

Enochian Biosciences

Investor Presentation

January 2024

Immix Biopharma

Investor Presentation

September 2023

Immatics

Investor Presentation

November 2023

Nuvalent

Investor Presentation

May 2023

Immix Biopharma

Investor Presentation

January 2024

Related decks

Nuvectis Pharma

Investor Presentation

July 2023

Immix Biopharma

Investor Presentation

August 2023

RenovoRx

IPO

August 2021

Enochian Biosciences

Investor Presentation

January 2024

Immix Biopharma

Investor Presentation

September 2023

Immatics

Investor Presentation

November 2023

Nuvalent

Investor Presentation

May 2023

Immix Biopharma

Investor Presentation

January 2024

Search Thousands of Presentations by World Leading Companies

Trending:

Addressable Market

Management Team

Investment Highlights